Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G/A for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 5%.
- Date of event: 31 Dec 2024.
ARMISTICE CAPITAL, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- IKT
- Shares outstanding
- 70,721,563 shares
- Disclosed Ownership
- 3,529,006 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 17:35:58 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 5% ownership in INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 17:35.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 5% | 3,529,006 | 0 | 3,529,006 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 5% | 3,529,006 | 0 | 3,529,006 | /s/ Steven Boyd | Steven Boyd |